HomeGMAB • NASDAQ
Follow
Genmab A/S - ADR
Previous close
$30.63
Day range
$29.84 - $30.56
Year range
$26.32 - $43.00
Market cap
19.54B USD
Avg Volume
626.22K
In the news
Financials
Income Statement
Revenue
Net income
(DKK) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 4.68B | -8.94% |
Operating expense | 2.88B | 14.18% |
Net income | 640.00M | 24.51% |
Net profit margin | 13.68 | 36.66% |
Earnings per share | 0.14 | -98.42% |
EBITDA | 1.73B | -35.13% |
Effective tax rate | 30.89% | — |
Balance Sheet
Total assets
Total liabilities
(DKK) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 28.14B | 26.03% |
Total assets | 35.29B | 17.17% |
Total liabilities | 3.68B | 29.68% |
Total equity | 31.61B | — |
Shares outstanding | 65.33M | — |
Price to book | 0.06 | — |
Return on assets | 11.84% | — |
Return on capital | 12.99% | — |
Cash Flow
Net change in cash
(DKK) | Dec 2023info | Y/Y change |
---|---|---|
Net income | 640.00M | 24.51% |
Cash from operations | 1.67B | 320.10% |
Cash from investing | -442.00M | -225.00% |
Cash from financing | -22.00M | -116.79% |
Net change in cash | 594.00M | 222.73% |
Free cash flow | 1.37B | 547.23% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.
The company has 8 approved antibodies used in 8 marketed products, covering cancer indications and autoimmune diseases.
Proprietary, marketed with partners:
Epkinly/Tepkinly for the treatment of Relapsed/refractory diffuse large B-cell lymphoma
Tivdak for the treatment of previously treated recurrent or metastatic cervical cancer
Marketed by partners:
Darzalex (IV) / Darzalex Faspro for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain amyloidosis
Kesimpta for the treatment of relapsing remitting multiple sclerosis
Rybrevant for the treatment of non-small-cell lung cancer Wikipedia
Founded
1999
Website
Employees
2,204